EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights

Carla Araya, Bárbara Mino, Patricio Le Cerf iD, Fancy Gaete, Ricardo Armisen iD, Daniel E Carvajal-Hausdorf

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252212246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Carla Araya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clínica Alemana Facultad de Medicina, Universidad del Desarrollo, Santiago 7650567, Chile. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo (ANID, Chile).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most common cancer among women and a leading cause of cancer-related deaths. PIK3CA gene mutations, which are often present in advanced HR+ breast cancer, can be targeted by alpelisib. However, data on PIK3CA mutations in Chile are limited. Here, we aim to assess the mutational status of PIK3CA in metastatic breast cancer tissues from Chilean patients and describe their clinicopathological characteristics and survival outcomes. We analyzed 102 formalin-fixed, paraffin-embedded metastatic breast cancer samples from 96 patients diagnosed at three Chilean hospitals between 2007 and 2023. PIK3CA mutations were identified using targeted sequencing, and clinicopathological data were collected. We evaluated associations between mutational status, clinicopathological features, and survival. The median age at diagnosis was 56 years. The most common metastatic sites were liver (29.4%), bone (17.6%), and lung/pleura (16.7%). Most patients were HR+ HER2− (83.3%), with 57.3% showing HER2-low status. PIK3CA mutations were present in 40.6% of patients, mainly in exons 7, 9, and 20. No significant associations were found between PIK3CA mutations and clinicopathological characteristics or survival. Our study reveals a high frequency of PIK3CA mutations in HR+ metastatic breast cancer, consistent with global data. The majority of mutations are targetable with alpelisib. The proportion of HER2-low status patients suggests potential benefits from novel HER2-targeted therapies. These findings highlight the need for routine molecular diagnostics in Chile to improve personalized treatment and address economic and access challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesBreast NeoplasmsMutationHumansFemaleMiddle AgedChileAgedAdultErb-b2 Receptor Tyrosine KinasesNeoplasm MetastasisReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorPrognosisAged, 80 and over

Stichwörter der Autor:innen

HER2-lowPIK3CA mutationsmetastatic hormone receptor-positive breast cancer

Substanzen

Class I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorPIK3CA protein, human

Autor:innen und Institutionen

  • Clínica Alemana Facultad de Medicina, Universidad del Desarrollo, Santiago 7650567, Chile.
  • Doctorado en Ciencias e Innovación en Medicina, Universidad del Desarrollo, Santiago 7610658, Chile.
  • Servicio de Anatomía Patológica, Hospital Dr. Sótero del Río, Santiago 7610658, Chile.
  • Servicio de Anatomía Patológica, Hospital Dr. Luis Tisné B, Santiago 7930426, Chile.
  • Instituto de Ciencias e Innovación en Medicina, Universidad del Desarrollo, Santiago 7610658, Chile.

ORCID-Profile: Patricio Le Cerf, Ricardo Armisen

Förderung

  • Agencia Nacional de Investigación y Desarrollo (ANID, Chile)

Zitieren

APA

Araya, C., Mino, B., Le Cerf, P., Gaete, F., Armisen, R., & Carvajal-Hausdorf, D. E. (2024). Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212246

Vancouver

Araya C, Mino B, Le Cerf P, Gaete F, Armisen R, Carvajal-Hausdorf DE. Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212246

BibTeX
@article{Araya2024,
  author = {Araya, Carla and Mino, Bárbara and Le Cerf, Patricio and Gaete, Fancy and Armisen, Ricardo and Carvajal-Hausdorf, Daniel E},
  title = {Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252212246}
}
Kostenlos starten →